The present disclosure belongs to the field of pharmaceuticals. Disclosed is a use of bulleyaconitine A in treating pruritus or a secondary lesion thereof, especially pruritus induced by histamine and/or chloroquine.

The present disclosure relates to the to the transdermal administration of THC and/or CBD and derivatives of these compounds, for the treatment and/or prevention and/or control of multiple sclerosis, multiple sclerosis-related muscle spasms, and pain and/or spasticity in multiple sclerosis.

The present invention provides a patch comprising a backing layer and an adhesive agent layer, wherein the adhesive agent layer is non-aqueous, the adhesive agent layer contains nonylic acid vanillylamide, terpene-based resin, rosin-based resin, styrene-isoprene-styrene block copolymer, and liquid paraffin, a mass ratio of a content of the terpene-based resin to a content of the rosin-based resin ((content of the terpene-based resin)/(content of the rosin-based resin)) in the adhesive agent layer is 0.45 to 1.3, and a mass ratio of a content of the styrene-isoprene-styrene block copolymer to a content of the liquid paraffin ((content of the styrene-isoprene-styrene block copolymer)/(content of the liquid paraffin)) in the adhesive agent layer is 0.45 to 1.2.

Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base.

A multilayer flexible film for packaging a transdermal patch product comprising a pharmaceutical active agent comprises: a product-contacting sealing layer comprising a co-polyester having a surface energy of at least 50 dyne/cm.sup.2; and one or more layers above the product-contacting sealing layer. The pharmaceutical active agent may comprise nicotine. An average adhesion force to peel the transdermal patch from the product-contacting sealing layer may be less than 100 g/inch (39.37 g/cm).

Provided is an adhesive sheet for affixation to the body which is excellent in enhancement and persistence of the blood circulation promoting action, has high affixability and conformability as a sheet, and is easily and widely applicable to the body in any use situation. That is, the present invention relates to an adhesive sheet for affixation to the body housed in a container, containing the following components (A) and (B): (A) bubbles containing carbon dioxide gas in a bubble fraction of 10% or more and 40% or less, and (B) water, wherein the total area occupied by bubbles having an imaginary diameter of 5 mm or more is 10% or less, in 100% of the surface area of the adhesive sheet for affixation to the body, a content of carbon dioxide gas in the total amount of the adhesive sheet for affixation to the body is from 100 to 20,000 ppm, and the adhesive sheet for affixation to the body is sealed in a low gas-permeable container.

The present invention provides a transdermal absorption preparation in which a drug-containing adhesive layer is formed on a support, the aforementioned adhesive layer contains at least a thermoplastic elastomer and a higher fatty acid ester, and a content of a tackifier is not more than 10 wt %, which is superior in drug solubility and releasability, as well as adhesiveness to the skin and low irritation to the skin.

Compositions and methods are provided for the prevention and treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1α in the wound.

There is provided a plastic material comprising at least one cannabinoid embedded within a structural polymer, wherein the plastic material is formulated to exude the at least one cannabinoid through an outer surface of the plastic material at a therapeutically effective rate for a period of at least a week or at least a month. The plastic material may comprise a liquid-absorbent material embedded within the structural polymer and a carrier oil absorbed into the liquid-absorbent material, wherein at least one cannabinoid is dissolved in the carrier oil.

A patch includes an adhesive laver, where the adhesive layer includes (a) 3-[(3R*,4R*)-3-(dimethylamionomethyl)tetrahydropyran-4-yl]phenol and (b) at least one selected from the group consisting of organic acids, amides, and alcohols, and an amount of the (b) is 50 parts by mass or greater relative to 100 parts mass of the (a). A production method of patch includes forming an adhesive layer with a mixture, where the mixture is obtained by mixing (a) 3-[(3R*,4R*)-3-(dimethylamionomethyl)tetrahydropyran-4-yl]phenol, and (b) a polar functional group-containing organic compound at 80° C. or lower.